| Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. | |
| | |
MedLine Citation:
|
PMID: 20561700 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Portal hypertension is the main cause of complications in patients with chronic liver disease. Over the past 25 years, progress in the understanding of the pathophysiology of portal hypertension was followed by the introduction of an effective pharmacological therapy, consisting mainly of treatments aimed at correcting the increased splanchnic blood flow. It is only recently that this paradigm has been changed. Progress in our knowledge of the mechanisms of increased resistance to portal blood flow, of the formation of portal-systemic collaterals, and of mechanisms other than vasodilatation maintaining the increased splanchnic blood flow have opened entirely new perspectives for developing more effective treatment strategies. This is the aim of the current review, which focuses on: (a) the modulation of hepatic vascular resistance by correcting the increased hepatic vascular tone due to hepatic endothelial dysfunction, and (b) correcting the abnormal angiogenesis associated with portal hypertension, which contributes to liver inflammation and fibrogenesis, to the hyperkinetic splanchnic circulation, and to the formation of portal-systemic collaterals and varices. |
| | |
Authors:
|
Jaume Bosch; Juan G Abraldes; Mercedes Fernández; Juan Carlos García-Pagán |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2010-06-01 |
Journal Detail:
|
Title: Journal of hepatology Volume: 53 ISSN: 0168-8278 ISO Abbreviation: J. Hepatol. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-17 Completed Date: 2010-12-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8503886 Medline TA: J Hepatol Country: England |
Other Details:
|
Languages: eng Pagination: 558-67 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
Affiliation:
|
Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic-IDIBAPS and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain. jbosch@clinic.ub.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antioxidants
/
therapeutic use Biopterin / analogs & derivatives, therapeutic use Endothelium, Vascular / physiopathology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Hypertension, Portal / pathology, physiopathology, therapy* Liver / blood supply, physiopathology Neovascularization, Pathologic Nitric Oxide / metabolism Prostaglandin-Endoperoxide Synthases / metabolism Prostaglandins / metabolism Signal Transduction Splanchnic Circulation / physiology Vascular Resistance |
| Chemical | |
Reg. No./Substance:
|
0/Antioxidants; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Prostaglandins; 10102-43-9/Nitric Oxide; 17528-72-2/5,6,7,8-tetrahydrobiopterin; 22150-76-1/Biopterin; EC 1.14.99.1/Prostaglandin-Endoperoxide Synthases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an upda...
Next Document: Non-alcoholic fatty liver disease, alcohol intake and psoriasis.